Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: Focus on dosing schedules

Medicine & Life Sciences

• bcr-abl Fusion Proteins 100%
• Philadelphia Chromosome 79%
• Imatinib Mesylate 70%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 64%
• Appointments and Schedules 50%
• Dasatinib 36%
• Leukemia, Myeloid, Chronic Phase 24%
• Leukemia, Myeloid, Accelerated Phase 15%
• Phosphotransferases 13%
• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 12%
• Genetic Code 12%
• Platelet-Derived Growth Factor Receptors 11%
• Therapeutics 10%
• Precursor Cell Lymphoblastic Leukemia-Lymphoma 8%
• Standard of Care 8%
• Interferons 8%
• Protein-Tyrosine Kinases 8%
• Safety 5%